Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

December 3, 2019December 3, 2019

Trials into Possible Treatment for Agitation in Alzheimer’s Patients to Continue, Avanir Says

News

A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. ... Read more

November 6, 2019November 6, 2019

$15M Investment Helps Secure Funding for Phase 2 Trial of T3D-959 for Alzheimer’s

News

T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as a potential treatment for people with mild-to-moderate Alzheimer’s disease. The total ... Read more

November 5, 2019November 5, 2019

Seaweed-based Therapy Approved in China for Mild to Moderate Alzheimer’s, 1st New Treatment in 16 Years

News

Oligomannate (GV-971), a compound derived from marine brown algae that promotes a healthy gut microbiome, is now conditionally approved in China to treat mild to moderate Alzheimer’s disease (AD), ... Read more

November 1, 2019November 1, 2019

INmune Bio’s XPro1595 May Help Lower Neuroinflammation Triggered by High Fat and Sugar Diet, Mouse Study Suggests

News

Treatment with INmune Bio‘s lead candidate XPro1595 can help decrease neuroinflammation and amyloid beta accumulation triggered by a diet high in sugar and fats, according to results from a ... Read more

October 25, 2019October 25, 2019

CareBand Tracking Bracelet Wins NIH Award, May Detect Agitation in Alzheimer’s, Related Dementias

News

CareBand’s tracking bracelet, which pairs GPS technology to track movement and activity in real time, has been granted the National Institutes of Health (NIH) Phase 1 Small Business Innovation ... Read more

October 16, 2019October 16, 2019

Oral Anticoagulant Dabigatran Prevented Memory Loss in Mouse Model of Alzheimer’s, Study Shows

News

Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in the brain and reduced the amount of senile plaques in ... Read more

October 9, 2019October 9, 2019

NDX-1017 Phase 1 Trial Complete, Results Will Be Presented at CTAD Conference, Athira Says

News

Athira Pharma has completed the Phase 1 trial testing NDX-1017, its lead therapeutic candidate for Alzheimer’s disease, and will present the results at the 12th Annual Clinical Trials on Alzheimer’s ... Read more

October 2, 2019October 2, 2019

Carefully Targeting Brain Immune Cells May Help Prevent Amyloid-beta Plaques, Study Suggests

News

Therapeutics that target brain immune cells known as microglia may prevent the formation of amyloid-beta plaques, one of the hallmarks of Alzheimer’s disease, according to a recent mouse study. ... Read more

September 23, 2019September 23, 2019

Phase 3 Trials of Elenbecestat in Early Alzheimer’s Stopped for Lack of Benefit, Eisai and Biogen Say

News

Two global Phase 3 clinical trials — MISSION AD1 (NCT02956486) and MISSION AD2 (NCT03036280) — evaluating elenbecestat as a potential therapy for early Alzheimer’s disease are being stopped early, Eisai and Biogen announced. This ... Read more

September 20, 2019September 20, 2019

Alzheimer’s Vaccine Found Safe, Effective in Patients with Mild Forms of the Disease, Phase 2 Study Finds

News

AXON Neuroscience’s investigational AADvac1 vaccine against tau protein, a hallmark of Alzheimer’s disease, was found safe and effective at lessening signs of neurodegeneration in patients with mild Alzheimer’s, according ... Read more

Pin It on Pinterest